Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 4/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.77 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.58 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.58 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.58 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.58 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.54 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | SHBG | P04278 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrahydrocortisone SCHEMBL1332665 | 1.00 | G6PD (0.79) | G6PDCYP3A4GABRA1GABRB2GABRG2 | |
| Tetrahydrocortisone SCHEMBL1184193 | 1.00 | G6PD (0.79) | G6PDCYP3A4GABRA1GABRB2GABRG2 | |
| Tetrahydrocortisone SCHEMBL5610354 | 1.00 | G6PD (0.79) | G6PDCYP3A4GABRA1GABRB2GABRG2 | |
| Tetrahydrocortisone SCHEMBL1184192 | 1.00 | G6PD (0.79) | G6PDCYP3A4GABRA1GABRB2GABRG2 | |
| Tetrahydrocortisone SCHEMBL193711 | 1.00 | G6PD (0.79) | G6PDCYP3A4GABRA1GABRB2GABRG2 | |
| Tetrahydrocortisone SCHEMBL5139991 | 0.99 | G6PD (0.77) | G6PDCYP3A4GABRA1GABRB2GABRG2 | |
| Tetrahydrocortisone SCHEMBL8366487 | 0.99 | G6PD (0.77) | G6PDCYP3A4GABRA1GABRB2GABRG2 | |
| Tetrahydrocortisone SCHEMBL8360187 | 0.99 | G6PD (0.77) | G6PDCYP3A4GABRA1GABRB2GABRG2 | |
| Tetrahydrocortisone SCHEMBL11169159 | 0.99 | G6PD (0.77) | G6PDCYP3A4GABRA1GABRB2GABRG2 | |
| Tetrahydrocortisone SCHEMBL6461669 | 0.99 | G6PD (0.77) | G6PDCYP3A4GABRA1GABRB2GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4295908-A2 | NEUROACTIVE STEROID FORMULATIONS COMPRISING A COMPLEX OF ALLOPREGNANOLONE AND SULFOBUTYL ETHER BETA-CYCLODEXTRIN | Sage Therapeutics, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| US-20230355639-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230225975-A1 | DEXAMETHASONE PRODRUG COMPOSITIONS AND USES THEREOF | RIPPLE THERAPEUTICS CORPORATION (CA) | 2023-07-20 | — | — | US | disclosed |
| US-20230149424-A1 | NEUROACTIVE STEROID FORMULATIONS AND METHODS OF TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| WO-2023079362-A1 | PROCESSABLE COMPOSITIONS AND USE FOR THE SAME | RIPPLE THERAPEUTICS CORPORATION (CA) | 2023-05-11 | — | — | WO | disclosed |
| US-20230141665-A1 | NEUROACTIVE STEROID SOLUTIONS AND THEIR METHODS OF USE | SAGE THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-11554125-B2 | Neuroactive steroids, compositions, and uses thereof | SAGE THERAPEUTICS, INC. (US) | 2023-01-17 | — | — | US | disclosed |
| EP-4003362-A1 | ARTICLES COMPRISING STEROID DIMERS AND THEIR USE IN THE DELIVERY OF THERAPEUTIC AGENTS | Ripple Therapeutics Corporation (CA) | 2022-06-01 | — | — | EP | disclosed |
| EP-3996764-A1 | SURFACE COATINGS AND IMPLANTABLE DEVICES COMPRISING DIMERIC STEROID PRODRUGS, AND USES THEREOF | Ripple Therapeutics Corporation (CA) | 2022-05-18 | — | — | EP | disclosed |
| US-11279729-B2 | Heterodimer compositions and methods for the treatment of ocular disorders | RIPPLE THERAPEUTICS CORPORATION (CA) | 2022-03-22 | — | — | US | disclosed |
| US-20170348326-A1 | NEUROACTIVE STEROID FORMULATIONS AND METHODS OF TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| EP-3191101-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | Sage Therapeutics, Inc. (US) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016205721-A1 | NEUROACTIVE STEROID SOLUTIONS AND THEIR METHODS OF USE | SAGE THERAPEUTICS, INC. (US) | 2016-12-22 | — | — | WO | disclosed |
| WO-2016040322-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
| US-20140057885-A1 | METHODS OF TREATING EPILEPSY OR STATUS EPILEPTICUS | SAGE THERAPEUTICS, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-8614203-B2 | Methods for the treatment of a central nervous system injury via a tapered administration protocol | EMORY UNIVERSITY (US) | 2013-12-24 | — | — | US | disclosed |
| US-20120289491-A1 | METHODS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM INJURY VIA A TAPERED ADMINISTRATION PROTOCOL | EMORY UNIVERSITY | 2012-11-15 | — | — | US | disclosed |
| US-20090221544-A1 | METHODS FOR THE TREATMENT OF A TRAUMATIC CENTRAL NERVOUS SYSTEM INJURY VIA A TAPERED ADMINISTRATION PROTOCOL | EMORY UNIVERSITY (US) | 2009-09-03 | — | — | US | disclosed |
| US-20050187188-A1 | Methods for the treatment of a traumatic central nervous system injury | EMORY UNIVERSITY (US) | 2005-08-25 | — | — | US | disclosed |
| US-20020072509-A1 | Methods for the treatment of a traumatic central nervous system injury | EMORY UNIVERSITY | 2002-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221544-A1 | METHODS FOR THE TREATMENT OF A TRAUMATIC CENTRAL NERVOUS SYSTEM INJURY VIA A TAPERED ADMINISTRATION PROTOCOL | CYP21A2, BDNF, CYP17A1 | G6PD 2934/4885CYP3A4 507/4885GABRA1 2369/4885 |
| US-20230149424-A1 | NEUROACTIVE STEROID FORMULATIONS AND METHODS OF TREATING CNS DISORDERS | NR3C2, NR3C1, HSD3B1 | G6PD 1588/4885CYP3A4 236/4885GABRA1 64/4885 |
| US-20230355639-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | GAP43, CYP17A1, HSD3B1 | G6PD 1622/4885CYP3A4 412/4885GABRA1 96/4885 |
| US-11279729-B2 | Heterodimer compositions and methods for the treatment of ocular disorders | CRYAB, UACA, CRYAA | G6PD 2109/4885CYP3A4 4704/4885GABRA1 1774/4885 |
| US-11554125-B2 | Neuroactive steroids, compositions, and uses thereof | GAP43, CYP17A1, HSD3B1 | G6PD 1622/4885CYP3A4 412/4885GABRA1 96/4885 |
| US-20120289491-A1 | METHODS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM INJURY VIA A TAPERED ADMINISTRATION PROTOCOL | CYP21A2, NR3C2, CYP11B2 | G6PD 2889/4885CYP3A4 495/4885GABRA1 1959/4885 |
| US-20140057885-A1 | METHODS OF TREATING EPILEPSY OR STATUS EPILEPTICUS | GRIK4, GABRE, GRIK2 | G6PD 3601/4885CYP3A4 483/4885GABRA1 60/4885 |
| US-20230141665-A1 | NEUROACTIVE STEROID SOLUTIONS AND THEIR METHODS OF USE | SHBG, CRH, NR3C2 | G6PD 2872/4885CYP3A4 598/4885GABRA1 347/4885 |
| US-20170348326-A1 | NEUROACTIVE STEROID FORMULATIONS AND METHODS OF TREATING CNS DISORDERS | NR3C2, NR3C1, HSD3B1 | G6PD 1588/4885CYP3A4 236/4885GABRA1 64/4885 |
| US-20230225975-A1 | DEXAMETHASONE PRODRUG COMPOSITIONS AND USES THEREOF | NR3C1, NR3C2, CYP21A2 | G6PD 86/4885CYP3A4 157/4885GABRA1 2946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.